Mirco Toccafondi graduated in Pharmaceutical Biotechnology (Università di Bologna, 2000) and obtained a Ph.D. in Chemical Science (Università di Firenze, 2012).
As a researcher in Universities, he gained expertise in structural and functional characterization of molecular targets involved in bacterial disease pathogenesis or neoplastic growth (Université Paris V, Università di Firenze, Università di Bolzano).
Work experiences in private companies (GSK, Siena) and scientific institutes as Istituto Nazionale di Genetica Molecolare (INGM, Milano), led him to improve skills in antigen characterization and proof of concept studies in vaccine developing.
Since October 2023, Mirco joined CheckmAb team as a biochemist for expressing and characterizing monoclonal antibodies for immunotherapy.